Skip to content
Retatrutide Guide

Reference · Source library

Source library

Every meaningful clinical, regulatory, and pricing claim across Retatrutide Guide is sourced from one of the references below. Each individual page also lists the specific sources it relies on.

Peer-reviewed publications

  1. 1.Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med, 2023. Source ↗
  2. 2.Rosenstock J, Frias J, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet, 2023. Source ↗
  3. 3.Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 2022. Source ↗
  4. 4.Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022. Source ↗
  5. 5.Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med, 2021. Source ↗

Regulatory & corporate

  1. 1.U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). FDA, 2026. Source ↗
  2. 2.Eli Lilly and Company. TRIUMPH retatrutide Phase 3 trial program. ClinicalTrials.gov, 2026. Source ↗
  3. 3.Eli Lilly and Company. LillyDirect / Zepbound self-pay program. lilly.com, 2026. Source ↗
  4. 4.Novo Nordisk. Wegovy and Ozempic patient cost information. novocare.com, 2026. Source ↗